Pharmaceuticals News and Research

RSS

Study finds patients treated with varespladib drug more likely to experience cardiovascular events

Patients with acute coronary syndrome who were treated with the experimental drug varespladib were more likely to experience additional cardiovascular events - including sudden death, heart attack and stroke - than those treated with placebo, according to research from the Cleveland Clinic Coordinating Center for Clinical Research (C5Research).

19 Nov 2013

Atopix recruits first patient in OC459 Phase 2 trial for treatment of atopic dermatitis

Atopix Therapeutics Ltd, a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the recruitment of the first patient in a six month Phase 2 clinical trial of its lead compound OC459 in moderate-to-severe atopic dermatitis (eczema).

19 Nov 2013

Study confirms therapeutic potential of inhibiting Aurora-A in cancer treatment

Aurora-A is a protein involved in the cell division process that is highly expressed or synthesised in a large number of human cancers, especially in those associated with a bad prognosis. Several pharmaceutical companies have recently developed these protein inhibitors, although the therapeutic and physiological effects that blocking Aurora-A might have on adult tissues are still unknown.

19 Nov 2013

Vismodegib drug does not offer added benefits for patients with BCC

The drug vismodegib (trade name: Erivedge) is approved for the treatment of patients with two forms of basal cell carcinoma: symptomatic metastatic BCC and locally advanced BCC inappropriate for surgery or radiotherapy.

19 Nov 2013

Kiadis reports successful Phase II enrollment for CR-AIR-007 ATIR blood cancer treatment study

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.

18 Nov 2013

Argos Soditic-managed funds announce acquisition of Cisbio Bioassays

The funds managed by Argos Soditic announce the acquisition, together with the management, of Cisbio Bioassays. This cutting-edge biotechnology company is the leader in the field of products and services for human in vitro diagnostics and pharmaceutical research.

18 Nov 2013

Researchers generate three-dimensional kidney structures from human stem cells

Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology.

18 Nov 2013

Eisai partners with NewBridge Pharmaceuticals to market Halaven drug in Middle East

Eisai announces today that Halaven (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals.

18 Nov 2013

New report addresses many changes that transform Medical Education landscape

Medical Education groups are often being transformed by regulatory and budget pressures, making it increasingly difficult to effectively educate healthcare practitioners on the safe and effective use of products. With the pressure to reduce budgets increasing within the pharmaceutical and medical device industries, it is absolutely critical for Medical Education groups to find practical and economical methods of reaching healthcare professionals.

16 Nov 2013

Study offers clearer explanation of the role of FOX01 molecule in wound-healing process

Skin provides a first line of defense against viruses, bacteria and parasites that might otherwise make people ill. When an injury breaks that barrier, a systematic chain of molecular signaling launches to close the wound and re-establish the skin's layer of protection.

16 Nov 2013

GSK and Save the Children to help roll out student-created breathing technology in Africa

A low-cost device that Rice University bioengineering students invented to help premature babies breathe more easily will be rolled out to teaching hospitals in three African nations, thanks to a $400,000 award from pharmaceutical giant GlaxoSmithKline and London-based charity Save the Children. The technology, which is known as "bubble CPAP," earned the top prize in GSK and Save the Children's inaugural Healthcare Innovation Award program.

15 Nov 2013

Research could refine next generation of drugs to help treat dementia

A £1.1 million grant to understand how one of the brain's key neurotransmitters called 'acetylcholine' influences brain activity has been awarded to University of Bristol researchers. The Wellcome Trust award will help scientists understand more precisely how the release of acetylcholine is changing brain cell activity to influence memory and cognition.

15 Nov 2013

WuXi PharmaTech subsidiary enters into supply arrangement with Pharmacyclics

WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that its wholly owned subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd., has entered into a supply arrangement with Pharmacyclics, Inc.

15 Nov 2013

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

15 Nov 2013

Designation of ISIS-GSK4Rx as a development candidate triggers milestone payment to Isis

Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the designation of ISIS-GSK4Rx as a development candidate. ISIS-GSK4Rx is an antisense drug designed to treat an undisclosed ocular disease.

15 Nov 2013

TPI’s revenue decreases 8.1% to $14.8 million in first quarter fiscal year 2014

Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the first quarter fiscal year 2014.

15 Nov 2013

Conceive Plus Fertility Personal Lubricant receives FDA approval

The Pew Research Center reports that in the year 2011, the birth rate in the United States slid by 8%. That kind of statistic would indicate getting pregnant isn't as easy as it used to be. However, pharmaceutical manufacturer SASMAR aims to be at the forefront of helping couples to start families. The FDA has officially approved their OTC sperm friendly fertility personal lubricant, Conceive Plus for sale in the US market.

15 Nov 2013

Viewpoints: Despite website woes, administration should be given more time; health law credibility 'going up in smoke'

The enrollment numbers are in, and as expected, they are well short of projections. Around 106,000 enrolled in new plans during October - with approximately 27,000 coming from states where the federal government is running the exchange (with its extensive problems), and another 79,000 coming through the state exchanges. Republicans are gleefully pointing to the numbers as proof Obamacare needs to be scrapped entirely. That confirms two things we've long known to be true: the website is a disaster, and short term enrollment figures are a serious political problem for the White House and Democrats (Greg Sargent, 11/13).

15 Nov 2013

Novel combination anti-psoriasis therapy targets genetic abnormalities in deeper layers of the skin

A novel combination anti-psoriasis therapy has potential for superior and longer-lasting therapeutic effects than current topical treatments by targeting genetic abnormalities in deeper layers of the skin. This research is being presented at the 2013 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in San Antonio, Nov. 10-14.

15 Nov 2013

FDA Advisory Committee votes in favor of Vanda's tasimelteon NDA for Non-24-Hour Disorder

Vanda Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee voted overwhelmingly to recommend the approval of Vanda's New Drug Application for tasimelteon, proposed tradename HETLIOZ™, for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind.

15 Nov 2013

Pharmaceuticals News and Research

Study finds patients treated with varespladib drug more likely to experience cardiovascular events

Atopix recruits first patient in OC459 Phase 2 trial for treatment of atopic dermatitis

Study confirms therapeutic potential of inhibiting Aurora-A in cancer treatment

Vismodegib drug does not offer added benefits for patients with BCC

Kiadis reports successful Phase II enrollment for CR-AIR-007 ATIR blood cancer treatment study

Argos Soditic-managed funds announce acquisition of Cisbio Bioassays

Researchers generate three-dimensional kidney structures from human stem cells

Eisai partners with NewBridge Pharmaceuticals to market Halaven drug in Middle East

New report addresses many changes that transform Medical Education landscape

Study offers clearer explanation of the role of FOX01 molecule in wound-healing process

GSK and Save the Children to help roll out student-created breathing technology in Africa

Research could refine next generation of drugs to help treat dementia

WuXi PharmaTech subsidiary enters into supply arrangement with Pharmacyclics

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Designation of ISIS-GSK4Rx as a development candidate triggers milestone payment to Isis

TPI’s revenue decreases 8.1% to $14.8 million in first quarter fiscal year 2014

Conceive Plus Fertility Personal Lubricant receives FDA approval

Viewpoints: Despite website woes, administration should be given more time; health law credibility 'going up in smoke'

Novel combination anti-psoriasis therapy targets genetic abnormalities in deeper layers of the skin

FDA Advisory Committee votes in favor of Vanda's tasimelteon NDA for Non-24-Hour Disorder

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence